Financings In Brief
This article was originally published in The Gray Sheet
Visx and Icahn part ways: Prompted by rejection of nominee Keith Meister to Visx' board of directors, financier Carl Icahn sells approximately 6 mil. shares of firm's stock to Goldman Sachs, of which 3.5 mil. shares were repurchased by Visx. The sale of Icahn's stake in the company ends a tumultuous relationship that began in August 2000 between the firm's single largest shareholder and Chairman/CEO Liz Davilla. Visx stock closed at $17.35 on May 29, the day of the announcement. Icahn's most notable confrontation with Visx' board was a $32-per-share hostile takeover bid for the company in April 2001 (1"The Gray Sheet" April 28, 2003, p. 22)...
You may also be interested in...
Visx plans to leverage its leadership position in LASIK system placements to market its custom wavefront-guided laser correction technology, which is expected to be approved by FDA this quarter
Medex will leverage the brand recognition of Ethicon Endo-Surgery Vascular Access' intravenous catheters to bolster its existing fluid and drug delivery systems
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.